UroGen Pharma Q2 2024 GAAP EPS $(0.91) Misses $(0.86) Estimate, Sales $21.848 Miss $23.963M Estimate
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma reported its Q2 2024 financial results, with a GAAP EPS of $(0.91), missing the estimate of $(0.86). Sales were $21.848 million, also missing the estimate of $23.963 million.
August 13, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UroGen Pharma's Q2 2024 financial results showed a GAAP EPS of $(0.91), missing the estimate of $(0.86). Sales were $21.848 million, also missing the estimate of $23.963 million.
The company's earnings and sales both missed analyst estimates, which is likely to negatively impact the stock price in the short term as investors react to the disappointing financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100